ENDRA Life Sciences (NDRA)
(Delayed Data from NSDQ)
$0.21 USD
0.00 (1.73%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.21 0.00 (1.94%) 7:28 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
ENDRA Life Sciences Inc. (NDRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.00 | $10.00 | $10.00 | 4,900.00% |
Price Target
Only one analyst offered a short-term price target of $10.00 for ENDRA Life Sciences Inc. This represents an increase of 4% from the last closing price of $0.20.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Buy-equivalent recommendation for ENDRA Life Sciences Inc. This translates to an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 2.00 a month ago based on just one Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/10/2024 | Ascendiant Capital Markets | Edward M Woo | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 1 |
Average Target Price | $10.00 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 60 of 252 |
Current Quarter EPS Est: | -1.78 |
NDRA FAQs
ENDRA Life Sciences Inc. (NDRA) currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for ENDRA Life Sciences Inc. (NDRA) is $10.00. The current on short-term price targets is based on 1 reports.
The forecasts for ENDRA Life Sciences Inc. (NDRA) range from a low of $10 to a high of $10. The average price target represents a increase of $4900.00 from the last closing price of $.20.
The current UPSIDE for ENDRA Life Sciences Inc. (NDRA) is 4900.00%
Only one analyst offered a short-term price target of $10.00 for ENDRA Life Sciences Inc. This represents an increase of 4% from the last closing price of $0.20.